<DOC>
	<DOCNO>NCT02480894</DOCNO>
	<brief_summary>This Phase 1 , open-label , single sequence , two-way interaction study healthy male female subject . - For effect maraviroc PK BMS-626529 ( active moiety BMS-663068 ) , formal hypothesis statistically test . The purpose assessment estimate effect maraviroc pharmacokinetics ( PK ) BMS-626529 coadministered healthy subject . - For effect BMS-663068 PK maraviroc , hypothesis statistically test BMS-663068 clinically significant effect PK maraviroc coadministered healthy subject .</brief_summary>
	<brief_title>A Open-label , Drug-Drug Interaction With Maraviroc</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy male female nonsmoking subject age 18 50 year , inclusive body mass index 18.0 32.0 kg/m2 , inclusive Women childbearing potential must agree follow instruction method contraception total 34 day posttreatment completion Any condition possibly affect drug absorption Preexisting liver dysfunction Any significant acute chronic medical illness Orthostatic intolerance Other protocol specify exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>